{"transactions":[{"id":2421164,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-31T21:30:36.000Z","date":"2022-01-31","kind":"purchase","acquired":true,"shares":800000,"price":27,"value":21600000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2735853,"source":{"system":"sec-edgar","filing":"0001213900-22-004647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004647/ownership.xml","form_type":"4"}},{"id":2422603,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":324740,"price":13.2,"value":4286568.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":107164},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422602,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":1455384,"price":13.2,"value":19211068.8,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":480277},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422601,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":75749,"price":13.2,"value":999886.8,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":24996},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422600,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":107164,"price":13.2,"value":1414564.8,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":431947,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422599,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":480277,"price":13.2,"value":6339656.4,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1935853,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422598,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":24996,"price":13.2,"value":329947.2,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":161712,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2872094,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":5655,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares subject to this warrant were fully vested prior to exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":5655},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872093,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":47718,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":47718},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872092,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":43901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":43901},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872091,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":150802,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":150802},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872090,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":40953,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares subject to this warrant were fully vested prior to exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":40953},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872089,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":345568,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":345568},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872088,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":317922,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":317922},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872087,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1092080,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1092080},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872086,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":false,"shares":17711,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares subject to this warrant were fully vested prior to exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":17711},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872085,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":472296,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":472296},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872084,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":944056,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":944056},"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872083,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":150000,"price":20,"value":3000000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held of record by Vivo Opportunity Fund, L.P. (VOF). Vivo Opportunity, LLC is the general partner of VOF and has four managing members."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872082,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":24267,"price":20,"value":485340.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":275789,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872081,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":20,"price":20,"value":400.0,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Upon closing of the Issuer's IPO, Vivo Capital Surplus Fund VIII, L.P. exercised a warrant to purchase 5,655 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo Capital Surplus Fund VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 20 share subject to the warrant in order to pay the exercise price and issuing to Vivo Capital Surplus Fund VIII, L.P. the remaining 5,635 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":251522,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872080,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":true,"shares":5655,"price":0.07,"value":395.85,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":251542,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872079,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":47718,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":245887,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872078,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":43901,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":198169,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872077,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":150802,"ownership":{"direct":false,"nature":"By Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":154268,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872076,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":175733,"price":20,"value":3514660.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1997216,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872075,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":144,"price":20,"value":2880.0,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Upon closing of the Issuer's IPO, Vivo Capital Fund VIII, L.P. exercised a warrant to purchase 40,953 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo Capital Fund VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 144 share subject to the warrant in order to pay the exercise price and issuing to Vivo Capital Fund VIII, L.P. the remaining 40,809 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1821483,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872074,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":true,"shares":40953,"price":0.07,"value":2866.71,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1821627,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872073,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":345568,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1780674,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872072,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":317922,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1435106,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872071,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":1092080,"ownership":{"direct":false,"nature":"By Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. Edgar Engleman is one of three voting members of Vivo Capital VIII, LLC."}],"balance_after":1117184,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872070,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":62,"price":20,"value":1240.0,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Upon closing of the Issuer's IPO, Vivo LP exercised a warrant to purchase 17,711 shares of the Issuer's Common Stock at an exercise price per share of $0.07. Vivo LP paid the exercise price on a cashless basis, resulting in the Issuer withholding 62 share subject to the warrant in order to pay the exercise price and issuing to Vivo LP the remaining 17,649 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":1448286,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872069,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"other","acquired":true,"shares":17711,"price":0.07,"value":1239.77,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":1448348,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872068,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":472296,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":1430637,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872067,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107996,"kind":"organization","name":"Vivo Panda Fund, L.P.","position":4,"cik":"0001675490","reported_name":"Vivo Panda Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107995,"kind":"organization","name":"Vivo Panda, LLC","position":5,"cik":"0001843847","reported_name":"Vivo Panda, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":7,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:37:46.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":944056,"ownership":{"direct":false,"nature":"By Vivo PANDA Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of\nthe Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by Vivo PANDA Fund, L.P. (\"Vivo LP\"). Vivo Panda, LLC (\"Vivo LLC\") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D. is one of four voting members of Vivo LLC."}],"balance_after":958341,"source":{"system":"sec-edgar","filing":"0001209191-21-008758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000120919121008758/doc4.xml","form_type":"4"}},{"id":2872066,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":50282,"ownership":{"direct":false,"nature":"Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50282},"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872065,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":364138,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":364138},"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872064,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":98484,"ownership":{"direct":false,"nature":"Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":216666},"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872063,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":713203,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1569047},"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872062,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":357353,"price":17,"value":6075001.0,"ownership":{"direct":false,"nature":"Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P.   Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P.  Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":357353,"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872061,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":14275,"price":17,"value":242675.0,"ownership":{"direct":false,"nature":"Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":281223,"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872060,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":103372,"price":17,"value":1757324.0,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2036557,"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872059,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":266948,"ownership":{"direct":false,"nature":"Vivo Capital Surplus Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":266948,"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":2872058,"issuer":{"id":49595,"kind":"organization","name":"Terns Pharmaceuticals, Inc.","symbol":"TERN"},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T20:08:19.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":1933185,"ownership":{"direct":false,"nature":"Vivo Capital Fund VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1933185,"source":{"system":"sec-edgar","filing":"0001567619-21-002591","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000156761921002591/doc1.xml","form_type":"4"}},{"id":3078896,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":4,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-07-22T00:25:08.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":3158851,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund IX, L.P. (VIVO IX LP). Vivo Capital IX, LLC (VIVO IX LLC) is the General Partner of VIVO IX LP. As the managing members of Vivo Capital IX, LLC, Frank Kung, Albert Cha, Edgar Engleman, Shan Fu and Chen Yu share voting and dispositive power with respect to the shares held of record by VIVO IX LP but each disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3158851},"source":{"system":"sec-edgar","filing":"0000899243-20-019915","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019915/doc4.xml","form_type":"4"}},{"id":3078895,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":4,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T00:25:08.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":185526,"price":19,"value":3524994.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by Vivo Opportunity Fund, L.P. (VOF). Vivo Opportunity, LLC is the general partner of VOF. As the managing members of Vivo Opportunity, LLC, Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang share voting and dispositive power with respect to the shares held of record by VIVO IX LP but each disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":185526,"source":{"system":"sec-edgar","filing":"0000899243-20-019915","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019915/doc4.xml","form_type":"4"}},{"id":3078894,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":4,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T00:25:08.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":3245048,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 86,197 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund IX, L.P. (VIVO IX LP). Vivo Capital IX, LLC (VIVO IX LLC) is the General Partner of VIVO IX LP. As the managing members of Vivo Capital IX, LLC, Frank Kung, Albert Cha, Edgar Engleman, Shan Fu and Chen Yu share voting and dispositive power with respect to the shares held of record by VIVO IX LP but each disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":4034522,"source":{"system":"sec-edgar","filing":"0000899243-20-019915","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019915/doc4.xml","form_type":"4"}},{"id":3078893,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":1,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":2,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":3,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":4,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T00:25:08.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":789474,"price":19,"value":15000006.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Vivo Capital Fund IX, L.P. (VIVO IX LP). Vivo Capital IX, LLC (VIVO IX LLC) is the General Partner of VIVO IX LP. As the managing members of Vivo Capital IX, LLC, Frank Kung, Albert Cha, Edgar Engleman, Shan Fu and Chen Yu share voting and dispositive power with respect to the shares held of record by VIVO IX LP but each disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":789474,"source":{"system":"sec-edgar","filing":"0000899243-20-019915","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019915/doc4.xml","form_type":"4"}},{"id":3216022,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-11T21:12:05.000Z","date":"2020-03-09","kind":"sale","acquired":false,"shares":133,"price":19.5,"value":2593.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.3 to $19.7, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Opportunity Fund, L.P. (\"VOF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":168165,"source":{"system":"sec-edgar","filing":"0001213900-20-006030","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020006030/ownership.xml","form_type":"4"}},{"id":3216021,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-11T21:12:05.000Z","date":"2020-03-09","kind":"sale","acquired":false,"shares":48,"price":19.5,"value":936.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.3 to $19.7, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":375880,"source":{"system":"sec-edgar","filing":"0001213900-20-006030","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020006030/ownership.xml","form_type":"4"}},{"id":3216020,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-11T21:12:05.000Z","date":"2020-03-09","kind":"sale","acquired":false,"shares":347,"price":19.5,"value":6766.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.3 to $19.7, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":2722045,"source":{"system":"sec-edgar","filing":"0001213900-20-006030","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020006030/ownership.xml","form_type":"4"}},{"id":3279903,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T01:00:51.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":5904,"price":21.4,"value":126345.6,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.4 to $21.6, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Opportunity Fund, L.P. (\"VOF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":168298,"source":{"system":"sec-edgar","filing":"0001213900-20-003326","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020003326/ownership.xml","form_type":"4"}},{"id":3279902,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T01:00:51.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":200,"price":21.4,"value":4280.0,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.4 to $21.6, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":375928,"source":{"system":"sec-edgar","filing":"0001213900-20-003326","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020003326/ownership.xml","form_type":"4"}},{"id":3279901,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T01:00:51.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":1451,"price":21.4,"value":31051.4,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.4 to $21.6, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":2722392,"source":{"system":"sec-edgar","filing":"0001213900-20-003326","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020003326/ownership.xml","form_type":"4"}},{"id":3279900,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T01:00:51.000Z","date":"2020-02-07","kind":"sale","acquired":false,"shares":4614,"price":22,"value":101508.0,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.9 to $22.2, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Opportunity Fund, L.P. (\"VOF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":174202,"source":{"system":"sec-edgar","filing":"0001213900-20-003326","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020003326/ownership.xml","form_type":"4"}},{"id":3279899,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T01:00:51.000Z","date":"2020-02-07","kind":"sale","acquired":false,"shares":157,"price":22,"value":3454.0,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.9 to $22.2, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":376128,"source":{"system":"sec-edgar","filing":"0001213900-20-003326","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020003326/ownership.xml","form_type":"4"}},{"id":3279898,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-12T01:00:51.000Z","date":"2020-02-07","kind":"sale","acquired":false,"shares":1134,"price":22,"value":24948.0,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.9 to $22.2, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":2723843,"source":{"system":"sec-edgar","filing":"0001213900-20-003326","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020003326/ownership.xml","form_type":"4"}},{"id":3286641,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-07T00:22:54.000Z","date":"2020-02-04","kind":"sale","acquired":false,"shares":10519,"price":22.8,"value":239833.2,"ownership":{"direct":false,"nature":"Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.2 to $23.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Opportunity Fund, L.P. (\"VOF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":178816,"source":{"system":"sec-edgar","filing":"0001213900-20-002831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002831/ownership.xml","form_type":"4"}},{"id":3286640,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-07T00:22:54.000Z","date":"2020-02-04","kind":"sale","acquired":false,"shares":357,"price":22.8,"value":8139.6,"ownership":{"direct":false,"nature":"Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.2 to $23.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":376285,"source":{"system":"sec-edgar","filing":"0001213900-20-002831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002831/ownership.xml","form_type":"4"}},{"id":3286639,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-07T00:22:54.000Z","date":"2020-02-04","kind":"sale","acquired":false,"shares":2584,"price":22.8,"value":58915.2,"ownership":{"direct":false,"nature":"Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.2 to $23.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":2724977,"source":{"system":"sec-edgar","filing":"0001213900-20-002831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002831/ownership.xml","form_type":"4"}},{"id":3296779,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-01T01:00:42.000Z","date":"2020-01-31","kind":"sale","acquired":false,"shares":4220,"price":21.7,"value":91574.0,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.2 to $22.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Opportunity Fund, L.P. (\"VOF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":189335,"source":{"system":"sec-edgar","filing":"0001213900-20-002314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002314/ownership.xml","form_type":"4"}},{"id":3296778,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-01T01:00:42.000Z","date":"2020-01-31","kind":"sale","acquired":false,"shares":143,"price":21.7,"value":3103.1,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.2 to $22.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":376642,"source":{"system":"sec-edgar","filing":"0001213900-20-002314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002314/ownership.xml","form_type":"4"}},{"id":3296777,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-01T01:00:42.000Z","date":"2020-01-31","kind":"sale","acquired":false,"shares":1037,"price":21.7,"value":22502.9,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.2 to $22.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":2727561,"source":{"system":"sec-edgar","filing":"0001213900-20-002314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002314/ownership.xml","form_type":"4"}},{"id":3296776,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-01T01:00:42.000Z","date":"2020-01-30","kind":"sale","acquired":false,"shares":5940,"price":22.1,"value":131274.0,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.9 to $22.5, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Opportunity Fund, L.P. (\"VOF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":193555,"source":{"system":"sec-edgar","filing":"0001213900-20-002314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002314/ownership.xml","form_type":"4"}},{"id":3296775,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-01T01:00:42.000Z","date":"2020-01-30","kind":"sale","acquired":false,"shares":201,"price":22.1,"value":4442.1,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.9 to $22.5, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":376785,"source":{"system":"sec-edgar","filing":"0001213900-20-002314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002314/ownership.xml","form_type":"4"}},{"id":3296774,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-01T01:00:42.000Z","date":"2020-01-30","kind":"sale","acquired":false,"shares":1459,"price":22.1,"value":32243.9,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.9 to $22.5, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":2728598,"source":{"system":"sec-edgar","filing":"0001213900-20-002314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002314/ownership.xml","form_type":"4"}},{"id":3296773,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-01T01:00:42.000Z","date":"2020-01-29","kind":"sale","acquired":false,"shares":10878,"price":22.2,"value":241491.6,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.1 to $22.5, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Opportunity Fund, L.P. (\"VOF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":199495,"source":{"system":"sec-edgar","filing":"0001213900-20-002314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002314/ownership.xml","form_type":"4"}},{"id":3296772,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-01T01:00:42.000Z","date":"2020-01-29","kind":"sale","acquired":false,"shares":369,"price":22.2,"value":8191.8,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.1 to $22.5, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":376986,"source":{"system":"sec-edgar","filing":"0001213900-20-002314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002314/ownership.xml","form_type":"4"}},{"id":3296771,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-01T01:00:42.000Z","date":"2020-01-29","kind":"sale","acquired":false,"shares":2673,"price":22.2,"value":59340.6,"ownership":{"direct":false,"nature":"See foonotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.1 to $22.5, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":2730057,"source":{"system":"sec-edgar","filing":"0001213900-20-002314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000121390020002314/ownership.xml","form_type":"4"}},{"id":3296793,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":4287,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F8","text":"Consists of 4,287 shares of Series A Preferred Stock held by Vivo Capital Fund IX, L.P., which are convertible into an aggregate of 324,783 shares of Common Stock, as adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":324783},"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296792,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":19213,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F7","text":"Consists of 19,213 shares of Series A Preferred Stock held by Vivo Opportunity Fund, L.P., which are convertible into an aggregate of 1,455,576 shares of Common Stock, as adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1455576},"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296791,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":1000,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F6","text":"Consists of 1,000 shares of Series A Preferred Stock held by Vivo Fund VII, which are convertible into an aggregate of 75,759 shares of Common Stock, as adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":75759},"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296790,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":324783,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":324783,"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296789,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":1455576,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1455576,"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296788,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":75759,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":136715,"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3579884,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-25T10:04:38.000Z","date":"2019-03-20","kind":"sale","acquired":false,"shares":83984,"price":22.25,"value":1868644.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Opportunity Fund, L.P. (\"VOF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Frank Kung, Albert Cha, Shan Fu, Gaurav Aggarwal and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes"}],"balance_after":210373,"source":{"system":"sec-edgar","filing":"0001615774-19-004434","document":"s116878_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577419004434/s116878_form4.xml","form_type":"4"}},{"id":3579883,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-25T10:04:38.000Z","date":"2019-03-20","kind":"sale","acquired":false,"shares":40407,"price":22.25,"value":899055.75,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":377355,"source":{"system":"sec-edgar","filing":"0001615774-19-004434","document":"s116878_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577419004434/s116878_form4.xml","form_type":"4"}},{"id":3579882,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":2,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":3,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":4,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":5,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-25T10:04:38.000Z","date":"2019-03-20","kind":"sale","acquired":false,"shares":292609,"price":22.25,"value":6510550.25,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":2732730,"source":{"system":"sec-edgar","filing":"0001615774-19-004434","document":"s116878_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577419004434/s116878_form4.xml","form_type":"4"}},{"id":3863748,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"exercise","acquired":false,"shares":187648,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":57035},"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}},{"id":3863747,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"exercise","acquired":false,"shares":1358903,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":413040},"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}},{"id":3863746,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"exercise","acquired":false,"shares":1163311,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":353590},"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}},{"id":3863745,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"exercise","acquired":false,"shares":8424416,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2560613},"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}},{"id":3863744,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"purchase","acquired":true,"shares":153180,"price":20.73,"value":3175421.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $19.25 to $24.5, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Vivo Opportunity Fund, L.P. (\"VOF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Vivo Opportunity, LLC is the general partner of VOF.  Vivo Capital LLC is the management company of Vivo Opportunity, LLC. The voting members of Vivo Opportunity, LLC are Frank Kung, Albert Cha, Shan Fu, Gaurav Aggarwal and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":294357,"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}},{"id":3863743,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"purchase","acquired":true,"shares":141177,"price":17,"value":2400009.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Vivo Opportunity Fund, L.P. (\"VOF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Vivo Opportunity, LLC is the general partner of VOF.  Vivo Capital LLC is the management company of Vivo Opportunity, LLC. The voting members of Vivo Opportunity, LLC are Frank Kung, Albert Cha, Shan Fu, Gaurav Aggarwal and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":141177,"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}},{"id":3863742,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"purchase","acquired":true,"shares":7137,"price":17,"value":121329.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":417762,"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}},{"id":3863741,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"purchase","acquired":true,"shares":51686,"price":17,"value":878662.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":3025339,"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}},{"id":3863740,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"exercise","acquired":true,"shares":57035,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":410625,"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}},{"id":3863739,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"exercise","acquired":true,"shares":413040,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":2973653,"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}},{"id":3863738,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"exercise","acquired":true,"shares":353590,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. (\"VCSF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":353590,"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}},{"id":3863737,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":92274,"kind":"organization","name":"Vivo Capital VIII, LLC","position":1,"cik":"0001618789","reported_name":"Vivo Capital VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":118091,"kind":"organization","name":"Vivo Capital, LLC","position":2,"cik":"0001674712","reported_name":"Vivo Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92275,"kind":"organization","name":"Vivo Capital Fund VIII, L.P.","position":3,"cik":"0001618788","reported_name":"Vivo Capital Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92276,"kind":"organization","name":"Vivo Capital Surplus Fund VIII, L.P.","position":4,"cik":"0001628048","reported_name":"Vivo Capital Surplus Fund VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":5,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":6,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-20T20:50:19.000Z","date":"2018-07-20","kind":"exercise","acquired":true,"shares":2560613,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by Vivo Capital Fund VIII, L.P. (\"VCF\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital VIII, LLC (\"Vivo LLC\") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes."}],"balance_after":2560613,"source":{"system":"sec-edgar","filing":"0001615774-18-006729","document":"s111487_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728970/000161577418006729/s111487_form4.xml","form_type":"4"}}]}